167 related articles for article (PubMed ID: 1069561)
1. Adoptive transfer and specific active immunization of patients with malignant melanoma.
Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
[No Abstract] [Full Text] [Related]
2. Immunotherapy in patients with melanoma.
Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
[No Abstract] [Full Text] [Related]
3. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
4. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
5. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
6. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
Kokoschka EM; Cerni C; Micksche M
Oncology; 1977; 34(5):229-33. PubMed ID: 917456
[TBL] [Abstract][Full Text] [Related]
7. Progress of immunotherapy in the treatment of malignant melanoma.
Ariyan S
Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
[No Abstract] [Full Text] [Related]
8. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
Mavligit GM; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for malignant melanoma with a tumor cell vaccine.
Slingluff CL; Seigler HF
Ann Plast Surg; 1992 Jan; 28(1):104-7. PubMed ID: 1642395
[TBL] [Abstract][Full Text] [Related]
10. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
11. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
12. Cell-mediated immunity in leprosy and transfer of delayed hypersensitivity reactions.
Mendes E; Raphael A; Mota NG; Mendes NF
J Allergy Clin Immunol; 1974 Apr; 53(4):223-9. PubMed ID: 4835734
[No Abstract] [Full Text] [Related]
13. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
14. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
Mavligit G; Gutterman JU; McBride C; Hersh EM
Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
[No Abstract] [Full Text] [Related]
15. Immunopathologic changes in patients with cutaneous malignant melanoma following intratumoral inoculation BCG: correlation with cell-mediated immunity.
Lieberman R; Epstein W; Fudenberg HH
Int J Cancer; 1974 Sep; 14(3):401-16. PubMed ID: 4617711
[No Abstract] [Full Text] [Related]
16. Immunity to neuroblastomas and melanomas.
Hellström KE; Hellström I
Annu Rev Med; 1972; 23():19-38. PubMed ID: 4566479
[No Abstract] [Full Text] [Related]
17. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR
J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886
[No Abstract] [Full Text] [Related]
18. Low doses of chemotherapy to inhibit suppressor T cells.
Berd D
Prog Clin Biol Res; 1989; 288():449-58. PubMed ID: 2566177
[No Abstract] [Full Text] [Related]
19. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
Shibata HR; Jerry LM; Lewis MG; Mansell PW; Capek A; Marquis G
Ann N Y Acad Sci; 1976; 277(00):355-66. PubMed ID: 1069555
[No Abstract] [Full Text] [Related]
20. Immunotherapy for human malignant melanoma.
Kopf AW
South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
